DOSSIERS
Hieronder vindt u een reeks artikelen die verband houden met het thema dat in deze sectie wordt behandeld. Deze content wordt aangeboden in de vorm van podcasts, interviews, video's, infographics,....
Fruzaqla Efficacy
FRESCO-2 was a global, randomized, double-blind, multicenter phase 3 study, evaluating the efficacy and safety of Fruzaqla + best supportive care (BSC) vs. Placebo + BSC.1,2
FRUZAQLA Safety Profile
In FRESCO-2, the majority of adverse events (AEs) with Fruzaqla were manageable and predictable1-3
Fruzaqla Mode of Action
Fruzaqla is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.1